Artificial intelligence-powered cardiovascular medicine company Cardio Diagnostics Holdings (NASDAQ: CDIO) was featured in a recent article that discussed its focus on cardiovascular disease prevention, detection, and management. The publication reads, “The company’s approach is centered on advancing how cardiovascular disease is addressed by moving beyond traditional methods that rely on indirect or generalized indicators… At the core of its strategy is the integration of epigenetics, genetics, and artificial intelligence to generate insights from a patient’s molecular profile. By analyzing both inherited predisposition and changes influenced by lifestyle and environment, the company’s platform is designed to provide a more complete view of cardiovascular disease.”
NOTE TO INVESTORS: The latest news and updates relating to CDIO are available in the company’s newsroom at https://nnw.fm/CDIO
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer